Recent studies have focused on the overlap of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopaminergic communication. While GIP stimulators are commonly employed for addressing type 2 diabetes mellitus, their emerging effects on reinforcement circuits, specifically governed by dopamine